Fig. 3

Dendrogram analysis exploring the anti-proliferative effects of targeted therapies in HNSCC slices. The analysis was conducted in the 14 HNSCC tumours, based on the calculated % inhibition of cell proliferation, i.e., based on the % of labelling of Ki67 in tumour cells, after normalization. Control condition for each tumour sample was taken as reference (100 %) for the calculation of the % inhibition of Ki67-labelling by each drug. This normalization step was applied in order to minimize the impact of the heterogeneous basal proliferative index of individual tumours, and in order to preferentially address the effects of the different drugs. Following this normalization, a cluster analysis was performed in order to identify drugs with neighbouring activities on Ki67 labelling. Bold and italic characters indicate conditions with a greater than 50 % inhibition of proliferation. Empty cases indicate conditions where tumour material was not sufficient for analysis